STEVEN FOSTER, MBA
CHAIR OF BOARD
Mr. Steven Foster is the Business Manager at Lawson Imaging, a branch of the Lawson Health Research Institute, which is a recognized leader in non-invasive biomedical imaging with new developments in hybrid imaging platforms such as PET/CT, SPECT/CT and MR/PET currently being applied to the areas of cardiology, neurology (including mental health), metabolic disease and cancer. Lawson Health Research Institute, located in London, Ontario, is one of Canada’s largest and most respected hospital-based research institutes and works in partnership with The University of Western Ontario.
KARIMAH ES SABAR
Karimah Es Sabar is CEO and Partner of Quark Venture Inc.
In her role as CEO & Partner at Quark Venture Ms. Es Sabar is also a Director of the Global Health Sciences Fund (GHS Fund), which was co-established with GF Securities, Hong Kong and which is one of the largest health sciences venture funds.
Prior to joining Quark Venture, Ms. Es Sabar led the Centre for Drug Research and Development (CDRD) as Canada’s national translation centre. She has an expansive global career spanning multi-national pharmaceutical/biotechnology companies (most notabl Sanofi Pasteur), start-ups, not-for-profit organizations and venture investment. Ms. Es Sabar has an extensive international experience and network, as well as leadership in marketing, business development, investment, strategic alliances, global collaborations and public private partnerships. She has raised enormous public and private sector funding, brought products to market, and has also developed and executed innovation and translation strategies in the life science sector and in biotech investment.
Ms. Es Sabar has received multiple awards and recognition for her pioneering work, including Canada’s Most Powerful Women: Top 100 Award. She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management; an MSc degree in Neurochemistry from the Institute of Psychiatry University of London, England ‒ and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.
Ms. Es Sabar has served on numerous private and public boards including the National Research Council Canada, Providence Healthcare Research Institute and the Vancouver Prostate Centre, as well as several health technology companies. Currently, she is Board Chair for TRIUMF Innovations and Chair of the Health Biosciences Economic Strategy Table for Government of Canada. As a thought leader on innovation ecosystems and on public private partnerships, she is a frequent keynote speaker.
Ms. Hayashi is the President and CEO of TRIUMF Innovations. Prior to TRIUMF Innovations, Ms. Hayashi was the Founding Chief Financial Officer of The Centre for Drug Research and Development (CDRD) and CDRD Ventures Inc, Canada’s national drug development and commercialization engine. As part of the founding team that started CDRD in 2007, she worked to develop a new partnership based model for translating and commercializing Canadian innovation and secure public and private sector funding totaling more than $230M. At CDRD she worked with a strong business-focused team to complete multiple transactions including the creation of 6 spin out companies (including a significant M&A exit) to establish CDRD as a leader in pre-clinical translational research and commercialization. Ms. Hayashi also presides as a Director and Audit Committee Chair of the Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont and has served on the boards of several CDRD spinoff companies. Ms. Hayashi has over 25 years of industry experience in all areas of operational and strategic planning, finance, and governance, and is a member of the Institute of Chartered Accountants of British Columbia.
FRANK GLEESON, MBA
Mr. Frank Gleeson has more than 20 years of leadership and business building experience as an operating executive and venture capitalist. During his career, he has completed more than $300 million in financing and partnering transactions. Mr. Gleeson is past chair of the board of the Stem Cell Network of Canada and in 2003 was recognized as a Technology Pioneer by the World Economic Forum. He has a number of entrepreneurial interests in the biomedical area outside of cancer. His previous experience includes roles as CEO of a professional services firm, as founding CEO of MDS Proteomics Inc. and as a senior vice president and partner at MDS Capital Corp. where he founded a dozen companies. Prior to MDS, he had a 16-year career with Imperial Chemical Industries PLC (ICI), both in Canada and the U.K., during which he was involved in technology commercialization in numerous fields. Mr. Gleeson holds an MBA degree from York University in Toronto.
Mr. James Schlosser is Senior Manager, Business Development & Contracts with the Provincial Health Authority’s Technology Development Office (TDO). In his role with the TDO, James is responsible for working closely with researchers from the BC Cancer Agency to take their promising inventions or discoveries to market. Prior to joining the TDO James was an investment analyst for Lions Capital, an investment banking and fund management firm which managed two venture capital funds, BC Advantage Funds (VCC) Ltd. and Lions Liquidity Investment Fund I LP, which invested in early stage life science and technology companies. James holds a BSc Biology from the University of Victoria and a BSc(Honours) in Oenology & Viticulture and an MSc Biology from Brock University..